---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-071756"
form_type: "8-K"
ticker: "A"
cik: "0001090872"
company_name: "AGILENT TECHNOLOGIES, INC."
filed_at: "2023-12-20T23:59:59+00:00"
generated_at: "2026-06-07T09:43:06.528001+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Agilent moves Cell Analysis Division into Diagnostics and Genomics Group

## Summary
- Cell Analysis Division moved from LSAG to DGG; effective Q1 fiscal 2024.
- Reorganization aims to strengthen growth opportunities and align with customer workflows.
- Historical segment financials for three prior years will be recast and filed in January 2024.
- Cell Analysis built via acquisitions of BioTek, ACEA, and Seahorse; remains key growth driver.

## SEC filing metadata
- accession: 0000950170-23-071756
- form_type: 8-K
- ticker: A
- cik: 0001090872
- company_name: AGILENT TECHNOLOGIES, INC.
- filed_at: 2023-12-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1090872/000095017023071756/0000950170-23-071756-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1090872/000095017023071756/a-20231220.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-071756
- JSON: https://secwatch.observer/filing/0000950170-23-071756.json
- Plain text: https://secwatch.observer/filing/0000950170-23-071756.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.